How Long Does Retatrutide Fatigue Last?

How long does retatrutide fatigue last is a question relevant to those enrolled in clinical trials investigating this unlicensed, investigational medicine. Retatrutide has no marketing authorisation in the UK or elsewhere and is available only within authorised research settings. Based on Phase 2 trial data published in the New England Journal of Medicine, fatigue was most commonly reported during the dose-escalation phase and appeared transient for most participants. No precise duration in days or weeks has been published. This article summarises what the available trial data report about fatigue and related side effects.

What is retatrutide and what is its regulatory status in the UK?

Retatrutide is an investigational triple agonist medicine with no UK marketing authorisation; it is available only within authorised clinical trials and cannot be prescribed or supplied through a GP, pharmacy or private clinic.

Retatrutide holds no marketing authorisation in the UK or anywhere else, meaning it can be prescribed or supplied only within an authorised clinical trial.^[15][16] It is an investigational medicine being studied for the management of obesity and type 2 diabetes. Unlike licensed treatments such as tirzepatide (Mounjaro) or semaglutide (Wegovy), retatrutide is not available through a GP, a pharmacy or any private clinic outside a formal research setting.

Retatrutide works by activating three hormone receptors simultaneously: the glucagon-like peptide-1 (GLP-1) receptor, the glucose-dependent insulinotropic polypeptide (GIP) receptor, and the glucagon receptor.^[1][2] This triple agonist mechanism distinguishes it pharmacologically from currently authorised dual or single agonist medicines. No published head-to-head data comparing retatrutide directly with licensed treatments are currently available.

Because retatrutide is investigational, the MHRA has not evaluated it for safety and efficacy in the way it would for a marketing authorisation application. Evidence comes from named clinical trials, including the Phase 2 programme published in the New England Journal of Medicine, the Phase 3 TRANSCEND-T2D-1 study, and the ongoing TRIUMPH programme, which has produced readouts presented at major diabetes and obesity congresses.^[1][3] These findings remain subject to full regulatory review.

Anyone who encounters retatrutide being sold online outside a clinical trial should be aware that such a product is not a licensed medicine and may be falsified or unsafe. If you are interested in licensed weight-management options, these can be discussed with your GP.

How long does fatigue typically last in retatrutide clinical trials?

No precise duration in days or weeks has been published; Phase 2 trial data indicate fatigue was most common during dose escalation and was generally transient for most participants.

Based on data from the Phase 2 retatrutide trial published in the New England Journal of Medicine, fatigue was reported as a side effect and was most commonly experienced during the dose-escalation phase of treatment rather than persisting throughout the study period.^[1][2] No specific median duration for fatigue has been published from the retatrutide trials, so it is not possible to state a precise number of days or weeks with accuracy.

In the Phase 2 trial, which enrolled adults with obesity over a 48-week period, fatigue was among the adverse events reported at a higher frequency in the retatrutide groups compared with placebo.^[1][3] The pattern was broadly consistent with what has been reported for other GLP-1 receptor agonist class medicines, where gastrointestinal and systemic symptoms such as fatigue tend to cluster around the period when doses are being increased.^[13] It should be noted that retatrutide also targets the glucagon receptor, so its full side-effect profile may differ from that of single or dual agonists, and class comparisons should be treated with caution.

Because dose escalation in the trial was gradual and structured, fatigue episodes were generally transient in nature for most participants. Individual experience varied, and the published data do not allow a single definitive answer about duration to be given for all participants. Phase 3 readouts from the TRANSCEND-T2D-1 study and TRIUMPH programme outputs have been reported at congresses including EASD and ADA, but detailed adverse event timelines for fatigue specifically have not yet been published in a form that allows precise duration estimates.^[5]

It is also worth considering common non-drug causes of fatigue, such as anaemia, hypothyroidism, vitamin B12 deficiency, sleep apnoea or low fluid intake. A GP can assess these and advise accordingly; the NHS provides patient-facing guidance on tiredness and fatigue at nhs.uk.

These observations come from controlled trial settings with close medical supervision and cannot be generalised to unsupervised use. Fatigue experienced outside a trial context should always be assessed by a healthcare professional.

What other side effects were reported alongside fatigue in trials?

The most frequently reported adverse effects in the Phase 2 trial were gastrointestinal, including nausea, vomiting, diarrhoea and constipation, alongside decreased appetite, headache, injection-site reactions and modest increases in resting heart rate.

In the Phase 2 retatrutide trial, the most frequently reported adverse effects were gastrointestinal in nature, and fatigue occurred alongside these in a proportion of participants. The gastrointestinal effects reported included nausea, vomiting, diarrhoea and constipation, and these were more common at higher dose levels and during periods of dose escalation.

Other adverse events reported in the trial included decreased appetite, which is pharmacologically expected given the mechanism of action across GLP-1, GIP and glucagon receptors. Injection-site reactions were also noted, as is common with subcutaneous injectable medicines. Headache was reported by some participants, and this too tended to be associated with the early treatment period.

The trial also collected data on heart rate, as glucagon receptor agonism can influence cardiovascular parameters. Modest increases in resting heart rate were observed in some participants, as reported in the Phase 2 trial data; the clinical significance of this finding is still under investigation and will require further characterisation from Phase 3 data before firm conclusions can be drawn.^[1][8]

As with other medicines in the GLP-1 receptor agonist class, acute pancreatitis is a safety area that trial investigators monitor carefully.^[14] The retatrutide trial data do not yet provide sufficient information to quantify this risk for this specific investigational compound, and no magnitude should be assumed.

Because retatrutide is investigational, all adverse events experienced by trial participants are reported to the trial team under the study protocol. Suspected side effects can also be reported to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk, which accepts reports for medicines used within clinical trials as well as for licensed products.

When should you seek medical advice about tiredness during a trial?

Trial participants should contact their trial team promptly if fatigue is severe, worsening or accompanied by symptoms such as severe abdominal pain, persistent vomiting, jaundice or palpitations, using 999 or A&E for immediately life-threatening emergencies.

Participants in a retatrutide clinical trial should contact their trial team promptly if fatigue is severe, worsening or accompanied by other concerning symptoms, as the trial protocol will specify the reporting requirements and thresholds for escalation. Trial participants have direct access to the research team and should use that route as their first point of contact for any symptom that concerns them.

If you need urgent or emergency care while enrolled in a trial, always tell the treating clinicians that you are participating in a clinical trial. Carry your study ID card and the trial team's contact details with you at all times, and share these with any clinician who assesses you. This allows emergency staff to take your trial medication into account when making treatment decisions.

Certain patterns of tiredness warrant more urgent attention. If fatigue is accompanied by severe abdominal pain, particularly pain that radiates to the back, this could indicate pancreatitis and should be assessed without delay. Persistent vomiting alongside fatigue that prevents adequate fluid intake raises the risk of dehydration and also requires prompt medical review. In these situations, if the trial team cannot be reached immediately, NHS 111 can provide urgent advice, and 999 or accident and emergency should be used for immediately life-threatening emergencies.

Fatigue that develops alongside yellowing of the skin or eyes, dark urine or pale stools may suggest a hepatic cause and should be reported to the trial team or a GP as soon as possible. Similarly, tiredness accompanied by palpitations, chest discomfort or significant breathlessness should be assessed promptly.

Most retatrutide trials exclude participants who are pregnant or breastfeeding, and effective contraception is typically required throughout the study period. If you think you may be pregnant, have become pregnant, or are breastfeeding while enrolled in a trial, contact your trial team immediately and do not stop or continue trial medication without their guidance.

For people who are not enrolled in a trial but are experiencing unexplained fatigue and are curious about investigational medicines, the appropriate route is a conversation with their GP about licensed treatment options. Retatrutide is not available outside an authorised clinical trial, and no timeline for UK authorisation can be given. Anything presented online as retatrutide outside a trial setting is not a licensed product and may pose serious safety risks.

Scientific References

1. Triple–Hormone-Receptor Agonist Retatrutide for Obesity (Jastreboff et al., Phase 2).
2. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist [Phase 2 T2D trial] (Rosenstock et al.).
3. Triple-Hormone-Receptor Agonist Retatrutide for Obesity [PubMed record, Jastreboff et al.].
4. Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity [Phase 3].
5. Retatrutide in adults with obesity and type 2 diabetes [TRANSCEND/EASD readout].
6. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial.
7. Retatrutide showing promise in obesity (and type 2 diabetes).
8. Retatrutide: a triple incretin receptor agonist for obesity management.
9. Advances in the management of obesity: non-pharmacological strategies, herbal formulations, current pharmacotherapy, emerging drugs, and future perspectives.
10. Cardiovascular effects of incretin receptor agonists: beyond glycemic control.
11. Incretin-based therapies in diabetic kidney disease: toward integrated cardio-kidney-metabolic disease modification.
12. Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2 trial.
13. GLP-1 receptor agonists: reminder of the potential side effects and to be aware of the potential for misuse.
14. GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists: strengthened warnings on acute pancreatitis, including necrotising and fatal cases.
15. Medicines and Healthcare products Regulatory Agency.
16. European Medicines Agency – What's new.
17. Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis.

Frequently Asked Questions